Get started
Author

Marta Ribelli

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
2020 · Miriam Grazia Ferrara, Vincenzo Di Noia, et al. · Cancers · 96
PDF
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center
2021 · G. Quero, L. Salvatore, et al. · ESMO Open · 34
PDF
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
2020 · Vincenzo Di Noia, Ettore D’Argento, et al. · Cancer Immunology Immunotherapy · 18
PDF
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
2021 · Miriam Grazia Ferrara, Maurizio Martini, et al. · Clinical Lung Cancer · 16
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
2023 · Carlo Signorelli, Maria Alessandra Calegari, et al. · Current Oncology · 13
PDF
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
2021 · Alessandro Parisi, Giampiero Porzio, et al. · Clinical Colorectal Cancer · 11
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)
2021 · Maria Alessandra Calegari, Lisa Salvatore, et al. · Cancers · 11
PDF
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study
2025 · Carlo Signorelli, Michele Basso, et al. · Cancers · 6
PDF
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
2024 · Carlo Signorelli, Maria Alessandra Calegari, et al. · Current Oncology · 6
PDF
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study
2025 · Carlo Signorelli, Maria Alessandra Calegari, et al. · Cancers · 4
PDF
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
2023 · Lisa Salvatore, Maria Bensi, et al. · Frontiers in Oncology · 4
PDF
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report
2021 · Maria Alessandra Calegari, Brunella Di Stefano, et al. · Clinical Colorectal Cancer · 4
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis
2023 · Carlo Signorelli, Mario Chilelli, et al. · Cancers · 1
PDF
617P Predictive and prognostic impact of primary tumor location on sequential treatment with regorafenib and trifluridine/tipiracil at third line and beyond in metastatic colorectal cancer: A real-world multicenter retrospective analysis
2023 · C. Signorelli, M.A. Calegari, et al. · Annals of Oncology · 1
PDF
DNA damage repair (DDR) germline mutations (GMs) in pancreatic ductal adenocarcinoma (PDAC): A mono-institutional retrospective study.
2022 · Maria Bensi, Angelo Minucci, et al. · Journal of Clinical Oncology · 1
P-74 The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study
2021 · M. Maratta, M. Chiaravalli, et al. · Annals of Oncology · 1
PDF
On-Treatment Grade 3–4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence
2026 · Carlo Signorelli, Michele Basso, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
PDF
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study
2023 · C. Signorelli, M. Calegari, et al. · Annals of Oncology
PDF
P-73 The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study
2021 · F. Camarda, F. Ardito, et al. · Annals of Oncology
PDF
The impact of first-line chemotherapy in elderly patients (pts) with advanced pancreatic cancer (APC): A mono-institutional retrospective study.
2021 · Marta Chiaravalli, Maria Grazia Maratta, et al. · Journal of Clinical Oncology
The role of site of metastatic resection (MR) in metastatic colorectal cancer (mCRC) patients (PTS): A mono-institutional cohort study.
2021 · Marta Ribelli, Francesco Ardito, et al. · Journal of Clinical Oncology
P-168 Second-line, anti-VEGF based after first-line, anti-EGFR based treatment in RAS wild-type metastatic colorectal cancer: The multicenter, retrospective, real-life SLAVE study
2020 · A. Parisi, F. Camarda, et al. · Annals of Oncology
P-152 The impact of 2nd-line treatment after 1st-line gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients
2020 · M. Bensi, B. Di Stefano, et al. · Annals of Oncology
P-103 The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study
2020 · F. Camarda, F. Ardito, et al. · Annals of Oncology
PDF
P-164 The role of response as a predictor of improved outcome in advanced pancreatic cancer patients treated with first-line gemcitabine plus nab-paclitaxel
2020 · M. Chiaravalli, M. Bensi, et al. · Annals of Oncology
Works count: 32
Citation count: 227
H-index: 7
I10-index: 7
Year
Topic
Type